Pat Beyer - 02 Mar 2026 Form 4 Insider Report for CONMED Corp (CNMD)

Reporting relationship: President & CEO
Issuer ticker: CNMD
Reported as of: 02 Mar 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 04 Mar 2026, 15:47:49 UTC
Prior SEC filing: 04 Jun 2025
Next SEC filing: 02 Apr 2026
Source filing: View source filing
Reporting owner signature: /s/ Thomas Fistek for Pat Beyer by Power of Attorney

Key filing fact

Pat Beyer filed Form 4 for CONMED Corp (CNMD) on 04 Mar 2026.

Key facts

This page summarizes Pat Beyer's Form 4 filing for CONMED Corp (CNMD).
2 reported transactions and 2 derivative rows are listed below.
Accepted by SEC: 04 Mar 2026, 15:47.

Change

Previous filing in this sequence was filed on 04 Jun 2025.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001627985 Primary reporting owner

Beyer Pat

Relationship: President & CEO
Address: C/O CONMED CORPORATION, 11311 CONCEPT BOULEVARD, LARGO
Signature: /s/ Thomas Fistek for Pat Beyer by Power of Attorney
Signature date: 04 Mar 2026

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

CNMD transaction Derivative

RSUs (Restricted Stock Units)

Award

Transaction value
Shares: +28,800
Change %
Price: $0.000000^*
Shares after: 28,800
Date: 02 Mar 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 28,800
Exercise price: $0.000000
Footnotes: F1

CNMD transaction Derivative

Options To Purchase Common Stock

Award

Transaction value
Shares: +68,258
Change %
Price: $0.000000^*
Shares after: 68,258
Date: 02 Mar 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 68,258
Exercise price: $45.79
Footnotes: F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

Each restricted stock unit ("RSU") represents a contingent right to receive one share of common stock, par value $0.01 per share of CONMED Corporation (the "Company") and will be subject to the terms and conditions of the Company's 2025 Long-Term Incentive Plan, with the RSUs generally vesting over a three-year period with the first 33% of the RSUs vesting one year after the grant date, 33% second year and 34% third year.

Footnote F2

The stock options were granted under CONMED Corporation Corporation's 2025 Long-Term Incentive Plan, with the stock options generally vesting in equal amounts over a four-year period with the first 25% of the stock options vesting one year after the grant date.